The Joint Blog

FEBRUARY 14, 2023

According to a recent poll by the American Psychiatric Association, many Americans are anticipating that 2023 will be a stressful year. The parent compound of CBD, CBDa has come to be known as a natural tool for inducing a relaxed state of mind, making it a crucial component of CBD oil for pain, sleep, and anxiety.

Sleep 26

Sleep Oil Chronic Pain Stress Management 26

Veriheal

JULY 9, 2021

Fortunately for those people, the cannabis plant’s active compounds AKA cannabinoids are being explored for their ability to treat cannabis withdrawal syndrome. For the past 25 years, Desouza has been investigating the world of cannabinoid treatment options. His most recent bout of research is already two years deep.

Treatment 52

Treatment Research and Development Consumption Sleep 52

Cannabis Law Report

SEPTEMBER 10, 2022

The Oregon legislative Task Force on Cannabis-Derived Intoxicants and Illegal Cannabis Production is exploring potential reforms to the state’s regulation of cannabinoid products and legislation for 2023 to combat what law enforcement believes is an increase in illicit marijuana production. concentration threshold.

Seed-To-Sale 52

Seed-To-Sale Hemp Cannabinoids Legislation 52

The Cannigma

AUGUST 14, 2023

Sleep is essential for overall health and well-being, and yet, many of us struggle to get a restful night’s sleep. From the daily stressors of life to hormonal changes, various factors can disrupt sleep patterns, especially for perimenopausal women. So, what’s a woman to do? But we’re not completely blind.

Sleep 65

Sleep CBD Cannabinoids THC 65

Cannabis Law Report

NOVEMBER 11, 2021

F) (the “Company” or “Canntab” ), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has received its medical sales license from Health Canada for its Markham, Ontario facility, enabling the sale of all products directly to medical consumers.

Events 52

Events Pharmaceutical Cannabinoids Patients 52

Project CBD

JUNE 20, 2023

Pain, anxiety, and sleep are major drivers of medical cannabis use. The endocannabinoid system is widely distributed throughout the gastrointestinal system, including not only CB1 and CB2 cannabinoid receptors but also other cannabinoid targets like PPARs, GPR55, and TRPV1.

Cannabinoids 208

Cannabinoids Patients Treatment Conditions 208

Project CBD

FEBRUARY 27, 2023

Across the eight studies they analyzed, the Australia-based authors identified increased levels of oleoylethanolamide and stearoylethanolamide (endocannabinoid-like molecules called N-Acylethanolamines that don’t bind with the cannabinoid receptors) in patients with these conditions compared to controls. © Copyright, Project CBD.

THC 144

THC CBD Sleep Clinical Trials 144

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

United Patients Group

DECEMBER 15, 2023

There is a stubborn stigma surrounding Cannabis and it no longer is simply that Cannabis has no merit or is an entrance drug, but that the non-psychoactive cannabinoid, CBD, is ALL you need for health, wellness, and other ailments which is not totally true. The same goes for using CBD only, we leave out other important cannabinoids.

CBD 119

CBD Terpenes Wellness and Beauty Cannabinoids 119

The Cannigma

OCTOBER 22, 2023

We need more data on “minor” cannabinoids, on terpenes, on specific cannabinoid ratios and formulations. On hemp-derived and synthetic cannabinoids alike. We need more data – human data – on specific applications for the plant – symptoms, use cases, conditions and patient types. The list goes on.

Data 88

Data Research and Development Sleep Collective 88

Project CBD

MAY 24, 2023

Ten years ago, most cannabis consumers couldn’t tell a terpene from a cannabinoid. A 2021 study 2 by University of Arizona scientists concluded that certain terpenes are “cannabimimetic” (in a mouse model of cannabis intoxication) and can selectively enhance cannabinoid activity. But today things are different.

Terpenes 274

Terpenes THC Cannabinoids Concentrates 274

MMJ Recs

OCTOBER 5, 2023

Maryland Medical Cannabis Strains Medical cannabis strains vary in their cannabinoid profiles and are tailored to address specific symptoms and conditions. Patients should be aware of their rights and responsibilities in the workplace and should communicate openly with their employers to address any concerns related to medical cannabis use.

Dispensary 52

Dispensary Patients Treatment Conditions 52

Illinois News Joint

MARCH 11, 2024

Arianne Richards, Executive Director of Chicago NORML, spoke next about what she regarded as, the “troubling mishandling of the petitions submitted in July 2023 to include four women’s health conditions on the list of qualifying conditions for the Medical Cannabis Program.” “Our

Conditions 88

Conditions Advocacy Patients Programs 88

Cannabis Law Report

JUNE 1, 2021

Implementation of supply chain optimization well underway with network optimization and complexity reduction initiatives expected to realize our previously stated cost savings of $150 million to $200 million by the end of the first half of FY 2023. About Canopy Growth Corporation. hemp industry in the U.S., hemp industry in the U.S.,

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

AUGUST 6, 2021

“We’re continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150 – $200 million in fiscal 2022- fiscal 2023,” added Mike Lee , CFO. “We The Ace Valley Dream gummies contain the CBN minor cannabinoid which lends itself to a key consumer need state, sleep.

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

DECEMBER 30, 2019

The law also expands the pool of patients eligible for cannabis therapy to include those diagnosed with post-traumatic stress, severe chronic pain, Crohn’s disease, Lou Gehrig’s disease, sleep apnea, and neuropathy, among other newly specified conditions. The law will take effect on January 1, 2020.

Legislation 59

Legislation Patients Access Banking 59